2013 Fiscal Year Final Research Report

Development of novel molecular targeted therapies for the treatment of KRas mutated non small lung cancer using a HSP90 inhibitor

Research Project

Project/Area Number	23592078
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Thoracic surgery
Research Institution	Kawasaki Medical School
Principal Investigator	MORITA ICHIRO 川崎医科大学, 医学部, 准教授 (30200413)
Project Period (FY)	2011 – 2013
Keywords	KRas / HSP90 / inhibitor
Research Abstract	Hsp90 inhibitors are substances that inhibit the activity of the Hsp90 heat shock protein. Since Hsp90 stabilizes a variety of proteins required for survival of cancer cells, these substances may have therapeutic benefit in the treatment of various types of malignancies. In the present study, we have evaluated the antitumor effects of a novel HSP90 inhibitor, AUY922 for the treatment of lung cancer. AUY922 suppressed cell viability and induced apoptosis in KRas addicted pulmonary adenocarcinoma cells. More, the inhibitor showed antitumor effect in EGFR-TK mutation or EML4-ALK positive lung cancer cells. These results indicate that AUY922 looks to be a promising treatment for non small cell lung cancer including pulmonary adenocarcinoma harboring KRas mutation.